119-HRES-1265 Journalist Public Summary

Headline Summary

The House is considering a bipartisan, nonbinding resolution to mark May 3–9, 2026 as “Tardive Dyskinesia Awareness Week,” encouraging Americans to learn about this medication-related movement disorder.

What It Does

In plain terms, the resolution voices the House’s support for an awareness week about tardive dyskinesia (TD) and urges people to get informed. It highlights that certain medicines (like some antipsychotics and anti-nausea drugs) can, with long-term use, lead to TD—uncontrollable movements of the face, torso, or limbs. It notes American Psychiatric Association guidance to regularly screen patients for TD and points out that FDA‑approved treatments for adults with TD exist. The measure does not change law or provide funding; it’s an official statement meant to raise visibility.

Who’s For It

Backers and what they say:

• Sponsors: Reps. Scott Peters (D‑CA), Gus Bilirakis (R‑FL), Kevin Mullin (D‑CA), and Aaron Bean (R‑FL) — a bipartisan group.
• Their case: Raising awareness can help patients and families recognize symptoms sooner, encourage regular screening by clinicians, and connect adults with FDA‑approved treatments.
• Public health and mental‑health advocates are typically aligned with awareness efforts that may reduce stigma and missed diagnoses.

Who’s Against It

What critics (if any) argue:

• No formal opposition noted at introduction.
• Common critique of awareness‑week resolutions: they are symbolic, consume floor time, and don’t direct resources to care or research.
• Some fiscal conservatives and process hawks sometimes prefer actionable bills (funding, coverage, or program changes) over commemorative measures.

What’s Next

Status: Introduced and referred to the House Committee on Energy and Commerce on May 7, 2026. Next, the committee may consider it or discharge it for a House vote. As a simple House resolution, if adopted it expresses the House’s position and does not go to the Senate or the President.